We next observed a significantly augmented proportion of samples with dosable circulating IL37 in patients suffering from an acute exacerbation of MS as compared to those with stable disease (34.6% vs. 8.4%; p = 0.0127, by chi square test with Yates’ correction). Here, IL37 is linked to myeloid sarcoma.